BR112012013975B8 - anticorpo monoclonal isolado, kit de diagnóstico, conjugado de anticorpo-fármaco, composição compreendendo o referido anticorpo, métodos in vitro para diminuir a atividade, para enfraquecer ou inibir o desenvolvimento de células e de detecção de expressão celular de b7h6, usos do anticorpo e do conjugado, e célula de produção de anticorpo - Google Patents

anticorpo monoclonal isolado, kit de diagnóstico, conjugado de anticorpo-fármaco, composição compreendendo o referido anticorpo, métodos in vitro para diminuir a atividade, para enfraquecer ou inibir o desenvolvimento de células e de detecção de expressão celular de b7h6, usos do anticorpo e do conjugado, e célula de produção de anticorpo

Info

Publication number
BR112012013975B8
BR112012013975B8 BR112012013975A BR112012013975A BR112012013975B8 BR 112012013975 B8 BR112012013975 B8 BR 112012013975B8 BR 112012013975 A BR112012013975 A BR 112012013975A BR 112012013975 A BR112012013975 A BR 112012013975A BR 112012013975 B8 BR112012013975 B8 BR 112012013975B8
Authority
BR
Brazil
Prior art keywords
antibody
conjugate
weakening
detection
composition
Prior art date
Application number
BR112012013975A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112012013975B1 (pt
BR112012013975A2 (pt
Inventor
Vivier Eric
Pierres Michel
Baratin Myriam
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43827827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012013975(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Publication of BR112012013975A2 publication Critical patent/BR112012013975A2/pt
Publication of BR112012013975B1 publication Critical patent/BR112012013975B1/pt
Publication of BR112012013975B8 publication Critical patent/BR112012013975B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112012013975A 2009-12-09 2010-12-08 anticorpo monoclonal isolado, kit de diagnóstico, conjugado de anticorpo-fármaco, composição compreendendo o referido anticorpo, métodos in vitro para diminuir a atividade, para enfraquecer ou inibir o desenvolvimento de células e de detecção de expressão celular de b7h6, usos do anticorpo e do conjugado, e célula de produção de anticorpo BR112012013975B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28501809P 2009-12-09 2009-12-09
US61/285,018 2009-12-09
PCT/IB2010/003411 WO2011070443A1 (en) 2009-12-09 2010-12-08 Monoclonal antibodies that bind b7h6 and uses thereof

Publications (3)

Publication Number Publication Date
BR112012013975A2 BR112012013975A2 (pt) 2017-01-10
BR112012013975B1 BR112012013975B1 (pt) 2021-01-12
BR112012013975B8 true BR112012013975B8 (pt) 2021-05-25

Family

ID=43827827

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012013975A BR112012013975B8 (pt) 2009-12-09 2010-12-08 anticorpo monoclonal isolado, kit de diagnóstico, conjugado de anticorpo-fármaco, composição compreendendo o referido anticorpo, métodos in vitro para diminuir a atividade, para enfraquecer ou inibir o desenvolvimento de células e de detecção de expressão celular de b7h6, usos do anticorpo e do conjugado, e célula de produção de anticorpo

Country Status (18)

Country Link
US (2) US8822652B2 (enExample)
EP (1) EP2510011B2 (enExample)
JP (2) JP2013513380A (enExample)
CN (2) CN104926942B (enExample)
BR (1) BR112012013975B8 (enExample)
CA (1) CA2783740C (enExample)
DK (1) DK2510011T3 (enExample)
EA (1) EA024629B1 (enExample)
ES (1) ES2523472T3 (enExample)
HR (1) HRP20141170T1 (enExample)
IN (1) IN2012DN04908A (enExample)
MX (1) MX2012006443A (enExample)
PL (1) PL2510011T3 (enExample)
PT (1) PT2510011E (enExample)
RS (1) RS53667B1 (enExample)
SI (1) SI2510011T1 (enExample)
SM (1) SMT201400184B (enExample)
WO (1) WO2011070443A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US12492376B2 (en) 2009-10-29 2025-12-09 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
HRP20141170T1 (hr) 2009-12-09 2015-01-30 Institut National de la Santé et de la Recherche Médicale Monoklonska antitijela koja se vežu za b7h6 i njihove uporabe
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
MX2014003065A (es) * 2011-09-13 2015-05-11 Deutsches Krebsforsch Anticuerpo monoclonal terapeuticamente activo b7-h6 contra el polipeptido b7-h6.
CN110511278B (zh) * 2012-05-07 2024-08-09 达特茅斯大学理事会 抗b7-h6抗体、融合蛋白及其使用方法
WO2014044799A1 (en) * 2012-09-21 2014-03-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for the diagnosing of inflammatory conditions involving detecting, identifying or assaying for soluble b7-h6 polypeptides
EP2711707A1 (en) 2012-09-21 2014-03-26 Institut Gustave Roussy Methods and kits for predicting the sensitivity of a subject to chemotherapy
WO2017181001A1 (en) * 2016-04-15 2017-10-19 Trustees Of Dartmouth College High affinity b7-h6 antibodies and antibody fragments
US11191771B2 (en) * 2016-06-09 2021-12-07 Seagen Inc. Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors
US20210170044A1 (en) * 2017-11-16 2021-06-10 Antigenesis Llc Systems and methods for lysosome induced immunogenic cell death
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
CN119661722A (zh) 2019-02-21 2025-03-21 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
GB2609554B (en) 2020-01-03 2025-08-20 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
WO2021143858A1 (en) * 2020-01-17 2021-07-22 Beigene, Ltd. ANTI-NKp30 ANTIBODIES AND METHODS OF USE
IL305847A (en) 2021-03-26 2023-11-01 Innate Pharma Multispecific proteins that contain a binding site for NKP46, a binding site for a cancer antigen that is fused to a cytokine to attract NK cells
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
WO2022258662A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a
CN114395045B (zh) * 2021-12-07 2023-06-09 合肥天港免疫药物有限公司 B7h6抗体及其应用
CN114395043B (zh) * 2021-12-07 2023-07-11 合肥天港免疫药物有限公司 Ncr3lg1抗体及其应用
CN114395047B (zh) * 2021-12-07 2023-11-07 合肥天港免疫药物有限公司 双特异性抗体及其应用
CN114395044B (zh) * 2021-12-07 2023-12-29 合肥天港免疫药物有限公司 重组抗体及其应用
CN114634574B (zh) * 2022-04-18 2022-12-20 先进生物(苏州)有限公司 抗B7H6的scFv抗体、其编码基因及其应用
KR20240003756A (ko) * 2022-06-29 2024-01-09 고려대학교 산학협력단 NKp30 결합력이 향상된 B7-H6 변이체
JP2025537792A (ja) * 2022-11-16 2025-11-20 ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ 疾患治療での使用のためのｔ細胞－ｎｋ細胞相互作用阻害剤
WO2024208818A1 (en) 2023-04-04 2024-10-10 Innate Pharma Modular chimeric antigen receptor

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
US4883662A (en) 1984-04-10 1989-11-28 Clinical Biotechnologies, Inc. Method of increasing natural killer cell population of cancer patients
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
FI102355B1 (fi) 1988-02-11 1998-11-30 Bristol Myers Squibb Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5082833A (en) 1988-06-30 1992-01-21 Shamsuddin Abulkalam M Reduction of cell proliferation and enhancement of nk-cell activity
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
JP3202999B2 (ja) 1991-01-31 2001-08-27 協和醗酵工業株式会社 肝移行性リポソーム製剤
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5556623A (en) 1993-03-30 1996-09-17 Eli Lilly And Company Antibody-drug conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
DE69626849T2 (de) 1995-12-22 2003-12-24 Bristol-Myers Squibb Co., Princeton Verzweigte hydrazongruppen enthaltende kuppler
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
CA2282504A1 (en) 1997-02-25 1998-08-27 Jun-Ping Xu Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
AU2769101A (en) * 2000-01-07 2001-07-24 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
JP4741838B2 (ja) 2002-07-31 2011-08-10 シアトル ジェネティクス，インコーポレーテッド 癌、自己免疫疾患または感染症を治療するための薬物結合体およびその使用
AU2003258714A1 (en) * 2002-09-06 2004-03-29 Cytos Biotechnology Ag Immune modulatory compounds and methods
WO2006124668A1 (en) * 2005-05-12 2006-11-23 Zymogenetics, Inc. Methods of using pnkp30, a member of the b7 family, to modulate the immune system
CA2682605A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
EA201000343A1 (ru) * 2007-10-04 2011-10-31 Займодженетикс, Инк. ЧЛЕН СЕМЕЙСТВА B7, zB7H6 И РОДСТВЕННЫЕ КОМПОЗИЦИИ И СПОСОБЫ
HRP20141170T1 (hr) 2009-12-09 2015-01-30 Institut National de la Santé et de la Recherche Médicale Monoklonska antitijela koja se vežu za b7h6 i njihove uporabe

Also Published As

Publication number Publication date
JP2017031147A (ja) 2017-02-09
ES2523472T3 (es) 2014-11-26
CA2783740C (en) 2020-03-10
EP2510011A1 (en) 2012-10-17
US20130004432A1 (en) 2013-01-03
CA2783740A1 (en) 2011-06-16
CN102741290A (zh) 2012-10-17
EA201270654A1 (ru) 2013-02-28
JP6212181B2 (ja) 2017-10-11
CN104926942A (zh) 2015-09-23
JP2013513380A (ja) 2013-04-22
CN102741290B (zh) 2015-04-22
RS53667B1 (sr) 2015-04-30
BR112012013975B1 (pt) 2021-01-12
SI2510011T1 (sl) 2014-12-31
WO2011070443A1 (en) 2011-06-16
US8822652B2 (en) 2014-09-02
DK2510011T3 (en) 2014-12-01
EP2510011B1 (en) 2014-09-17
PL2510011T3 (pl) 2015-02-27
CN104926942B (zh) 2018-09-14
HRP20141170T1 (hr) 2015-01-30
BR112012013975A2 (pt) 2017-01-10
US9663577B2 (en) 2017-05-30
US20150056214A1 (en) 2015-02-26
EP2510011B2 (en) 2021-03-31
MX2012006443A (es) 2012-06-28
PT2510011E (pt) 2014-12-12
SMT201400184B (it) 2015-01-15
EA024629B1 (ru) 2016-10-31
IN2012DN04908A (enExample) 2015-09-25

Similar Documents

Publication Publication Date Title
BR112012013975B8 (pt) anticorpo monoclonal isolado, kit de diagnóstico, conjugado de anticorpo-fármaco, composição compreendendo o referido anticorpo, métodos in vitro para diminuir a atividade, para enfraquecer ou inibir o desenvolvimento de células e de detecção de expressão celular de b7h6, usos do anticorpo e do conjugado, e célula de produção de anticorpo
BRPI0910746B8 (pt) agente de reticulação, conjugado de agente de ligação celular-fármaco, seu uso, composto e composição farmacêutica
AU2011343161A8 (en) Human anti-SOD1 antibodies
AR069980A1 (es) Inmunoconjugados dirigidos contra cd 138 y sus usos
ECSP11011297A (es) Proteinas ligadoras il-17
WO2009046407A3 (en) B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
BR112013010853A2 (pt) "agentes citotóxicos compreendendo derivados de ansamitocina, composição farmacêutica e uso destes"
CO6630137A2 (es) Pirrolobenzodiacepinas y conjugados de las mismas
BRPI0817427A8 (pt) anticorpo anti-bst2
CR10459A (es) Derivados de leptomicina
AR069747A1 (es) Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion
CL2023001966A1 (es) Conjugados de anticuerpo dirigido a b7-h4 y fármaco, y métodos de uso de los mismos
BR112014003999A2 (pt) anticorpo isolado que se liga a um epítopo próximo da membrana de mcsp humano, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de indivíduos portadores de câncer, método de undução da lise celular em indivíduos e teste imuno-histoquímico de mcsp
WO2011069104A3 (en) Multispecific antibodies, antibody analogs, compositions, and methods
BR112012011268A2 (pt) anticorpos anti-integrina ligados a nanopartículas carregadas com agentes quimioterapêuticos
BRPI0510716A (pt) uso de um agente de ligação bi-especìfico, agente de ligação bi-especìfico, composição de um agente de ligação bi-especìfico, e, kit
BRPI0906435B8 (pt) Anticorpo anti-cd79b quimérico, composto conjugado, formulação farmacêutica, método para determinar a presença da proteína cd79b, ensaio para detectar células de câncer, método para inibir proliferação celular, usos de um anticorpo, de um composto conjugado e de uma formulação farmacêutica, e método para a fabricação de um composto conjugado
BR112018067379A2 (pt) conjugado anticorpo-droga, composição, método para tratamento de um paciente que tem ou corre o risco de ter um câncer, para produzir o conjugado anticorpo-droga ou a composição, para determinar se um paciente será responsivo a um tratamento com o conjugado anticorpo-droga ou a composição, e, uso de um conjugado anticorpo-droga ou de uma composição.
BR112015014751A2 (pt) anticorpos anti-tau humanos
MX2010000537A (es) Anticuerpos monoclonales contra glipicano-3.
BR112018013407A2 (pt) anticorpos e conjugados dos mesmos
BRPI0821003B8 (pt) método para aumentar a imunorreatividade
NI200900022A (es) Anticuerpo especifico de prlr y usos del mismo
NZ595574A (en) Anti-fcrh5 antibodies and immunoconjugates and methods of use

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/12/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.